AstraZeneca Gets Profit Boost From Diabetes, Cancer Drugs
AstraZeneca posted higher profit in the first quarter, driven by sales of its diabetes and cancer medicines. The British drugmaker confirmed its guidance for the year and also said it was committed to investing and growing in the US as the industry braces for tariffs. AstraZeneca CEO speaks on Bloomberg TV's Guy Johnson, Kriti Gupta and Anna Edwards.
Terms and Privacy Policy